REPORTS & PUBLICATIONS

PCOR-ANZ Annual Report 2024: Prostate Cancer Across Australia and New Zealand

PCOR-ANZ Annual Report 2024: Prostate Cancer Across Australia and New Zealand

If you don't measure something, it's hard to manage it. That's the idea behind PCOR-ANZ, one of the largest prostate cancer registries in the world. With data on almost 175,000 men across Australia and New Zealand, it tracks how prostate cancer is diagnosed, treated and lived with, so care keeps getting better for the men who need it.

Who it’s for

HEALTH PRACTITIONERS

To benchmark care against national patterns and identify where practice can improve.

GOVERNMENT & POLICY MAKERS

To identify gaps in timely and equitable care across states, and provide targeted investment and funding to close those gaps.

RESEARCHERS & ACADEMICS

To access one of the world's largest bi-national prostate cancer datasets.

MEN WITH LIVED EXPERIENCE & THEIR FAMILIES

To understand what treatment could mean for their own experience, from diagnosis through to recovery.

KEY FINDINGS

56,677 men diagnosed with prostate cancer were added to PCOR-ANZ between 2020 and 2022, giving clinicians and researchers a clearer, more complete picture of care across the region.

20,550

the number of men registered in 2022 alone, the highest annual total since the registry began

85%

of men with low-risk prostate cancer were managed with Active Surveillance (close monitoring) in 2022, up from 66% in 2015

73%

of men received a pre-biopsy MRI in 2022, up from just 5.6% in 2015

258

the number of hospitals and clinics that contributed data in 2024

EXPLORE THE RESEARCH

Click through the tabs to explore the research in more detail.

PCOR-ANZ is one of the most representative prostate cancer datasets in the world, capturing most men diagnosed across the region.

  • An estimated 72% of all men diagnosed with prostate cancer in Australia and New Zealand in 2022 are captured in PCOR-ANZ
  • Western Australia joined the registry for the first time in 2025, moving PCOR-ANZ toward full national coverage
  • The median age at diagnosis rose to 69 in 2022, reflecting a broader shift toward older age at diagnosis